Importantly, our results indicate that in lymphoma patients, PD1 and PD-L1 IgG2 AAbs are highly produced in ~20% patients who respond to anti-PD1 therapy (Figure 6A, Figure S5-S7). The gene discussed is PDCD1; the disease is lymphoma.